标准剂量与高剂量利福平治疗肺结核:系统综述与Meta分析
该系统综述与Meta分析纳入8项随机对照试验共1897例初治肺结核患者,比较标准剂量(10 mg/kg)与高剂量利福平。高剂量组第8周痰培养阴转率高于标准剂量组(83.7% vs 80.6%,RR 1.06,95%CI 1.01–1.12,P=0.028),在≥20 mg/kg亚组中亦获证实;治疗失败与安全性事件无显著差异。
要点
- 高剂量利福平可提高第8周痰培养阴转率,尤其在≥20 mg/kg时
- 11–19 mg/kg亚组未见痰培养阴转率显著获益
- 治疗失败率及3/4级肝毒性、停药不良反应无显著差异
核心结论
- 高剂量利福平与第8周痰培养阴转率升高相关,尤其在≥20 mg/kg患者中。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、Google Scholar和Cochrane Library,纳入8项随机对照试验共1897例初治肺结核患者,比较标准剂量(10 mg/kg)与高剂量利福平。
主要发现
- 第8周高剂量组痰培养阴转率83.7%,标准剂量组80.6%(RR 1.06,95%CI 1.01–1.12,P=0.028)。
- ≥20 mg/kg亚组痰培养阴转获益获证实,11–19 mg/kg亚组未获证实。
- 治疗失败率两组无显著差异(RR 0.84,95%CI 0.59–1.21,P=0.362)。
- 3/4级肝毒性发生率两组无显著差异(7.2% vs 5.4%,RR 1.19,95%CI 0.81–1.73,P=0.370)。
- 导致停药的不良反应发生率两组无显著差异(1.5% vs 0.6%,RR 2.31,95%CI 0.65–8.21,P=0.195)。
关键数值与推荐
- 高剂量组第8周痰培养阴转率83.7%,标准剂量组80.6%(RR 1.06,95%CI 1.01–1.12,P=0.028)。
- ≥20 mg/kg亚组痰培养阴转获益获证实,11–19 mg/kg亚组未获证实。
- 治疗失败率RR 0.84(95%CI 0.59–1.21,P=0.362)。
- 3/4级肝毒性发生率7.2% vs 5.4%(RR 1.19,95%CI 0.81–1.73,P=0.370)。
- 导致停药的不良反应发生率1.5% vs 0.6%(RR 2.31,95%CI 0.65–8.21,P=0.195)。
临床怎么用
- 对初治肺结核患者,高剂量利福平可能提高第8周痰培养阴转率,≥20 mg/kg时获益更明确,安全性未见显著增加。
局限性
- 纳入8项随机对照试验中3项偏倚风险低、2项高、3项中等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: A growing amount of evidence suggests that the rifampicin dosing currently recommended for tuberculosis treatment could be associated with inadequate exposure and unfavourable outcomes. We aimed to compare clinical and microbiological efficacy and safety outcomes of standard and higher rifampicin dosing. METHODS: Data sources were MEDLINE, Google Scholar and the Cochrane Library. This was a systematic review and meta-analysis that included experimental or observational studies comparing 8-week sputum culture conversion, treatment failure, or safety outcomes in naïve patients with pulmonary tuberculosis treated with standard (10 mg/kg) or higher doses of rifampicin. RESULTS: Of a total of 9683 citations screened, eight randomized controlled trials were included, accounting for 1897 subjects; the risk of bias was low in three studies, high in two and intermediate in three. At week 8 a higher proportion of patients in the high-dose group obtained a sputum culture conversion than those in the standard dose group (83.7% versus 80.6%, RR 1.06; 95%CI 1.01-1.12, p 0.028); this result was confirmed in the sub-analysis including patients treated with a rifampicin dose of ≥20 mg/kg, but not in those treated with 11-19 mg/kg. Events of treatment failure at end of treatment showed no significant difference between the two groups (RR 0.84; 95%CI 0.59-1.21, p 0.362). In the analysis evaluating safety outcome, the difference in the occurrence of a grade 3 or 4 liver toxicity or adverse drug reactions leading to discontinuation was not significant at the statistical analysis among the groups (7.2% versus 5.4%, RR 1.19; 95%CI 0.81-1.73, p 0.370, and 1.5% versus 0.6%, RR 2.31; 95%CI 0.65-8.21, p 0.195, respectively). No statistical heterogeneity among studies was observed for each outcome. CONCLUSIONS: High doses of rifampicin were associated with an increased rate of sputum culture conversion at 8 weeks of treatment, particularly in patients receiving ≥20 mg/kg.
引用
- Onorato L, Gentile V, Russo A, et al. Standard versus high dose of rifampicin in the treatment of pulmonary tuberculosis: a systematic review and meta-analysis. Clin Microbiol Infect. 2021. PMID: 33813119. doi:10.1016/j.cmi.2021.03.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。